166 related articles for article (PubMed ID: 28964448)
21. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
[TBL] [Abstract][Full Text] [Related]
22. The EQ-5D-5L Valuation study in Thailand.
Pattanaphesaj J; Thavorncharoensap M; Ramos-Goñi JM; Tongsiri S; Ingsrisawang L; Teerawattananon Y
Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):551-558. PubMed ID: 29958008
[TBL] [Abstract][Full Text] [Related]
23. Assessing quality of life in a clinical study on heart rehabilitation patients: how well do value sets based on given or experienced health states reflect patients' valuations?
Leidl R; Schweikert B; Hahmann H; Steinacker JM; Reitmeir P
Health Qual Life Outcomes; 2016 Mar; 14():48. PubMed ID: 27005466
[TBL] [Abstract][Full Text] [Related]
24. Investigating 5-Level EQ-5D (EQ-5D-5L) Values Based on Preferences of Patients With Heart Disease.
Gandhi M; Tan RS; Lim SL; Rand K; Lam CSP; Luo N; Cheung YB
Value Health; 2022 Mar; 25(3):451-460. PubMed ID: 35227458
[TBL] [Abstract][Full Text] [Related]
25. The performance of a value set for the EQ-5D based on experienced health states in patients with inflammatory bowel disease.
Leidl R; Reitmeir P; König HH; Stark R
Value Health; 2012 Jan; 15(1):151-7. PubMed ID: 22264983
[TBL] [Abstract][Full Text] [Related]
26. Chinese time trade-off values for EQ-5D health states.
Liu GG; Wu H; Li M; Gao C; Luo N
Value Health; 2014 Jul; 17(5):597-604. PubMed ID: 25128053
[TBL] [Abstract][Full Text] [Related]
27. Sample size determination for EQ-5D-5L value set studies.
Gandhi M; Xu Y; Luo N; Cheung YB
Qual Life Res; 2017 Dec; 26(12):3365-3376. PubMed ID: 28825183
[TBL] [Abstract][Full Text] [Related]
28. Valuation of Health States Considered to Be Worse Than Death-An Analysis of Composite Time Trade-Off Data From 5 EQ-5D-5L Valuation Studies.
Gandhi M; Rand K; Luo N
Value Health; 2019 Mar; 22(3):370-376. PubMed ID: 30832976
[TBL] [Abstract][Full Text] [Related]
29. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.
Oppe M; Devlin NJ; van Hout B; Krabbe PF; de Charro F
Value Health; 2014 Jun; 17(4):445-53. PubMed ID: 24969006
[TBL] [Abstract][Full Text] [Related]
30. Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach.
Pullenayegum EM; Chan KK; Xie F
Med Decis Making; 2016 Feb; 36(2):223-33. PubMed ID: 26139449
[TBL] [Abstract][Full Text] [Related]
31. Valuation of Quality Weights for EuroQol 5-Dimensional Health States With the Time Trade-Off Method in the Capital of Iran.
Goudarzi R; Sari AA; Zeraati H; Rashidian A; Mohammad K; Amini S
Value Health Reg Issues; 2019 May; 18():170-175. PubMed ID: 31096140
[TBL] [Abstract][Full Text] [Related]
32. EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom.
Hernandez Alava M; Wailoo A; Grimm S; Pudney S; Gomes M; Sadique Z; Meads D; O'Dwyer J; Barton G; Irvine L
Value Health; 2018 Jan; 21(1):49-56. PubMed ID: 29304940
[TBL] [Abstract][Full Text] [Related]
33. The EQ-5D-5L Improves on the EQ-5D-3L for Health-related Quality-of-life Assessment in Patients Undergoing Total Hip Arthroplasty.
Greene ME; Rader KA; Garellick G; Malchau H; Freiberg AA; Rolfson O
Clin Orthop Relat Res; 2015 Nov; 473(11):3383-90. PubMed ID: 25488404
[TBL] [Abstract][Full Text] [Related]
34. Exploring the importance of controlling heteroskedasticity and heterogeneity in health valuation: a case study on Dutch EQ-5D-5L.
Karim S; Craig BM; Groothuis-Oudshoorn CGM
Health Qual Life Outcomes; 2022 May; 20(1):85. PubMed ID: 35614472
[TBL] [Abstract][Full Text] [Related]
35. The impact of differences between patient and general population EQ-5D-3L values on the mean tariff scores of different patient groups.
Little MH; Reitmeir P; Peters A; Leidl R
Value Health; 2014 Jun; 17(4):364-71. PubMed ID: 24968996
[TBL] [Abstract][Full Text] [Related]
36. EQ-5D-5L in the General German Population: Comparison and Evaluation of Three Yearly Cross-Section Surveys.
Huber MB; Reitmeir P; Vogelmann M; Leidl R
Int J Environ Res Public Health; 2016 Mar; 13(3):. PubMed ID: 27007387
[TBL] [Abstract][Full Text] [Related]
37. Elicitation of Norwegian EQ-5D-5L values for hypothetical and experience-based health states based on the EuroQol Valuation Technology (EQ-VT) protocol.
Hansen TM; Helland Y; Augestad LA; Rand K; Stavem K; Garratt A
BMJ Open; 2020 Jun; 10(6):e034683. PubMed ID: 32532768
[TBL] [Abstract][Full Text] [Related]
38. Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores.
McClure NS; Sayah FA; Xie F; Luo N; Johnson JA
Value Health; 2017 Apr; 20(4):644-650. PubMed ID: 28408007
[TBL] [Abstract][Full Text] [Related]
39. The effect of health state selection on the valuation of EQ-5D.
Chuang LH; Kind P
Med Decis Making; 2011; 31(1):186-94. PubMed ID: 20671210
[TBL] [Abstract][Full Text] [Related]
40. Application of EQ-5D-5L questionnaire in patients suffering from urinary incontinence.
Garcia-Gordillo MA; Collado-Mateo D; Olivares PR; Adsuar JC
Actas Urol Esp; 2016 Sep; 40(7):457-62. PubMed ID: 26975979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
